

## News Release

# Strategic Partnership Agreement with Norwich Capital Limited

Tokyo, Japan – March 13, 2026 — Nano Holdings, Inc. (TSE Growth Market: 4571; Chairman, President and CEO Atsushi Matsumura) today announced that it has entered into a strategic partnership agreement with Norwich Capital Limited (hereinafter referred to as “Norwich”), an investment company based in Hong Kong.

Through this partnership, the investment platform of the NANO Group, which aims to enhance the value of outstanding Japanese technologies to a global level and achieve successful exits through trilateral collaboration among Japan, the United States, and China, will be strengthened.

### 1 . About Norwich Capital Limited

Norwich is a financial advisor and SPAC sponsor with a track record of structuring and listing more than 10 SPACs on the U.S. Nasdaq market (including CADT, TOTA, AGBA, and KVAC) and has been referred to as the “Asia’s SPAC Godfather” by major international media such as Bloomberg.

Jason Wong, the founder and chairman, has built a strong network of leading investors through transactions such as the approximately USD 4 billion merger between AGBA and Triller Corp., and through his previous firm Transpac Capital made an early investment in Alibaba (ROI of 59x).

In addition to its network in the Chinese market, Norwich’s extensive network with U.S. institutional investors and PIPE investors, together with its track record of more than 10 Nasdaq-listed SPACs, will support the realization of global exits for NANO’s portfolio companies.



### 2 . Overseas Strategy of the NANO Group

In the healthcare and biotechnology sectors, NANO possesses a wide range of deal opportunities in Japan, including publicly listed biotech ventures, privately held healthcare-related companies, pharmaceutical company pipelines, and corporate carve-out opportunities from major companies. In addition, centered around Neil W. Gibson, Chairman of Nano Holdings US, LLC, NANO has built strong networks with venture capital firms and entrepreneurs in the United States and promotes deal development from a global perspective.

### 3 . China Participation Realized through the Partnership with Norwich and the Evolution into a Tri-Regional Strategy

Through this partnership, “China” will be added to the overseas expansion that has been based on a Japan–U.S. dual structure, thereby strengthening it into a trilateral structure. With the participation of China, value creation for portfolio companies will be accelerated through the following three pathways.

- 1) Creation of Licensing-Out Opportunities  
Technologies and pipelines held by NANO's portfolio companies will be licensed to Chinese companies through Norwich's network, enabling both early monetization and expansion into the Chinese market.
- 2) Expansion of Assets through Licensing-In  
By licensing in promising pipelines from China to portfolio companies, development assets will be expanded and competitiveness in global competition will be enhanced.
- 3) Cost Reduction and Speed Improvement through Clinical Trials in China  
NANO will also explore clinical development strategies utilizing China that may enable significant cost reductions and faster development timelines compared with conducting clinical development solely in Japan and the United States.

This matter will have no impact on the financial results for the fiscal year ending March 2026, and NANO will continue to contribute to strengthening the international competitiveness of Japan's healthcare and biotechnology industry.

Investor and Media Contact  
Nano Holdings, Inc.  
Corporate Communication  
<https://www.nano-hd.com/en>